SCHEMBL25823409

SCHEMBL25823409

CN1CCCN(c2ccc(Nc3nc4ccc(/C(C=N)=C/N)cc4n4ccnc34)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 3/20 0.43
EGFR P00533 4/20 0.38
MAPK8 P45983 2/20 0.38
MAPT P10636 1/20 0.37
ATM Q13315 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LCK P06239 1/20 0.37
CCNK O75909 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CCND3 P30281 1/20 0.37
CDK9 P50750 1/20 0.37
CDK6 Q00534 1/20 0.37
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
SRC P12931 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25823859 0.87 MAPK8 (0.40) MAPKAPK5MAPK8CD63SYK
SCHEMBL26184439 0.87 MAPK8 (0.38) MAPKAPK5MAPK8MAPTATMTDP1
SCHEMBL25822740 0.82 MAPKAPK5 (0.51) MAPKAPK5EGFRMAPTATMTDP1
SCHEMBL21949405 0.80 PYGM (0.44) EGFRSRCTECSLKBRD4
SCHEMBL25824383 0.78 MAPK8 (0.43) MAPKAPK5MAPK8LCKIKBKBSYK
SCHEMBL25822735 0.78 MAPKAPK5 (0.52) MAPKAPK5EGFRMAPTHTR3EHTR3B
SCHEMBL25822739 0.78 MAPKAPK5 (0.49) MAPKAPK5EGFRMAPTATMTDP1
SCHEMBL25823831 0.77 SYK (0.49) CD63SYK
SCHEMBL25822689 0.76 MAPKAPK5 (0.51) MAPKAPK5EGFRMAPKAPK2FLT3STK17A
SCHEMBL25823381 0.76 MAPKAPK5 (0.50) MAPKAPK5EGFRHTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 SYK, KDR, FLT1 MAPKAPK5 216/4885EGFR 313/4885MAPK8 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.